S. Lauer
Hoffmann-La Roche
8 Papers
39 Citations
S. Lauer is an academic researcher from Hoffmann-La Roche. The author has contributed to research in topics: Trastuzumab & Population. The author has an hindex of 4, co-authored 7 publications.
Chat about Author
Papers
11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial
David Cameron,Martine Piccart-Gebhart,Richard D. Gelber,Richard D. Gelber,Marion Procter,Aron Goldhirsch,Evandro de Azambuja,Gilberto de Castro,Michael Untch,Ian E. Smith,Luca Gianni,José Baselga,N. Al-Sakaff,S. Lauer,Eleanor McFadden,Brian Leyland-Jones,Richard Bell,Mitch Dowsett,Christian Jackisch +18 more
TL;DR: 1 year of adjuvant trastuzumab after chemotherapy for patients with HER2-positive early breast cancer significantly improves long-term disease-free survival, compared with observation.
925
Role of Troponins I and T and N-Terminal Prohormone of Brain Natriuretic Peptide in Monitoring Cardiac Safety of Patients With Early-Stage Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Receiving Trastuzumab: A Herceptin Adjuvant Study Cardiac Marker Substudy.
Dimitrios Zardavas,Thomas M. Suter,Dirk J. van Veldhuisen,Jutta Steinseifer,Johannes Noe,S. Lauer,N. Al-Sakaff,Martine Piccart-Gebhart,Evandro de Azambuja +8 more
TL;DR: Elevated troponin I or T before trastuzumab is associated with increased risk for TRCD and a similar conclusion for NT-proBNP could not be drawn because of the lack of a well-established elevation threshold; however, higher increases from baseline were seen in patients with T RCD compared with patients without.
137
Switching between intravenous and subcutaneous trastuzumab: Safety results from the PrefHer trial.
Joseph Gligorov,Giuseppe Curigliano,Volkmar Müller,Ann Knoop,Valerie Jenkins,Sunil Verma,S. Osborne,S. Lauer,Z. Machackova,Lesley Fallowfield,Xavier Pivot +10 more
TL;DR: PrefHer revealed that switching from IV to SC trastuzumab (hand-held syringe or SID) or vice versa did not impact the known safety profile of trastzumab.
22
Adjuvant Subcutaneous Trastuzumab for HER2-Positive Early Breast Cancer: Subgroup Analyses of Safety and Active Medical Conditions by Body Weight in the SafeHer Phase III Study
Kyung Hae Jung,Beyhan Ataseven,Mark Verrill,Xavier Pivot,Michelino De Laurentiis,N. Al-Sakaff,S. Lauer,M. Shing,Joseph Gligorov,Hamdy A. Azim +9 more
TL;DR: The data support the use of fixed-dose H SC as an adjuvant therapy in HER2-positive EBC and confirm the comparable safety profile of H SC in patients with low body weight or of Asian origin versus the overall population in SafeHer.
15
Empagliflozin in patients with type 2 diabetes mellitus and chronic obstructive pulmonary disease.
Stefan D. Anker,Leif E. Sander,David Fitchett,Bernard Zinman,A. Pernille Ofstad,Christoph Wanner,Ola Vedin,S. Lauer,Subodh Verma,H. Klar Yaggi,Silvio E. Inzucchi +10 more
TL;DR: In the EMPA-REG OUTCOME trial as discussed by the authors , patients with Type 2 diabetes mellitus (T2DM) and chronic obstructive pulmonary disease (COPD) were treated with empagliflozin (10 mg or 25 mg) or placebo.
5